Related Experiment Video
Updated: Mar 22, 2026

Quantifying Acute Changes in Renal Sympathetic Nerve Activity in Response to Central Nervous System Manipulations in Anesthetized Rats
Published on: September 11, 2018
Neural modulation for hypertension and heart failure
S Smith1, P Rossignol2, S Willis1
1The Ohio State University Wexner Medical Center, Department of Internal Medicine and Division of Cardiology, Columbus, OH, USA.
Insights
Neuromodulation offers new hope for resistant hypertension and heart failure. Exploring therapies like renal denervation and vagal stimulation may improve outcomes when combined with existing treatments.
Area of Science:
- Cardiovascular Medicine
- Neurology
- Medical Technology
Background:
- Hypertension (HTN) and heart failure (HF) significantly increase global morbidity and mortality.
- Sub-optimal HTN treatment elevates risks for stroke, renal failure, and HF.
- Outcomes for HF patients remain poor despite current pharmacological and device therapies.
Purpose of the Study:
- To review the evidence for neuromodulation in treating resistant HTN and HF.
- To explore synergistic effects of neuromodulation with existing drug and device therapies.
- To outline strategies for improving future neuromodulation trial success.
Main Methods:
- Review of current evidence on neuromodulation techniques.
- Analysis of neuromodulation in relation to established treatments (pharmacologic, CRT, ICDs).
- Discussion of lessons learned from recent neuromodulation trials.
Main Results:
- Neuromodulation, including renal denervation, baro-reflex modulation, and vagal stimulation, shows potential for resistant HTN and HF.
- Potential for synergistic effects exists when combining neuromodulation with conventional therapies.
- Insights gained from past trials can guide future research and improve success rates.
Conclusions:
- Neuromodulation represents a promising frontier for managing treatment-resistant hypertension and heart failure.
- Further research and optimized trial designs are crucial for realizing the full potential of these therapies.
- Combining neuromodulation with existing treatments may offer enhanced therapeutic benefits for patients.
Abstract:
Hypertension (HTN) and heart failure (HF) have a significant global impact on health, and lead to increased morbidity and mortality. Despite recent advances in pharmacologic and device therapy for these conditions, there is a need for additional treatment modalities. Patients with sub-optimally treated HTN have increased risk for stroke, renal failure and heart failure. The outcome of HF patients remains poor despite modern pharmacological therapy and with established device therapies such as CRT and ICDs. Therefore, the potential role of neuromodulation via renal denervation, baro-reflex modulation and vagal stimulation for the treatment of resistant HTN and HF is being explored. In this manuscript, we review current evidence for neuromodulation in relation to established drug and device therapies and how these therapies may be synergistic in achieving therapy goals in patients with treatment resistant HTN and heart failure. We describe lessons learned from recent neuromodulation trials and outline strategies to improve the potential for success in future trials. This review is based on discussions between scientists, clinical trialists, and regulatory representatives at the 11th annual CardioVascular Clinical Trialist Forum in Washington, DC on December 5-7, 2014.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Neural Regulation of Blood Pressure
Baroreceptor Reflex
Baroreceptors, located in the carotid sinuses and aortic arch, detect changes in blood pressure. When blood pressure rises, these stretch-sensitive receptors...
Heart Failure II: Pathophysiology
Heart Failure V: Medical Management
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Diuretics

